Skip to content

Remote Ischemic Conditioning of the Human Brain in Dementia Patients

Remote Ischemic Conditioning of the Human Brain in Dementia Patients (RICBDE): Protocol for a Crossover Non-pharmaceutical Intervention Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04168021
Acronym
RICBDE
Enrollment
90
Registered
2019-11-19
Start date
2020-01-01
Completion date
2021-12-31
Last updated
2019-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia, Intermittent Claudication, Mild Cognitive Impairment

Brief summary

The study investigates the incidence of remote ischemic conditioning in mild cognitive impairment and dementia patients

Detailed description

The investigators will study the potential neuroprotection of ischemia/reperfusion (I/R) of a peripheral organ or tissue against cerebral I/R injury in people with mild cognitive impairment as well as early and middle stage dementia. This crossover study will be held with individuals suffering from peripheral arteriopathy that can cause intermittent claudication after structured exercise, thus inducing extensive transient leg's ischemia.

Interventions

BEHAVIORALLeg ischemia

potential neuroprotection of ischemia/reperfusion of a peripheral organ or tissue against cerebral I/R injury

Sponsors

Greek Alzheimer's Association and Related Disorders
CollaboratorOTHER
Aristotle University Of Thessaloniki
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
65 Years to 95 Years
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of mild cognitive impairment * Clinical diagnosis of mild dementia * Clinical diagnosis of moderate dementia * Peripheral arteriopathy

Exclusion criteria

* Clinical diagnosis of severe dementia * Not being able to follow the exercise program for more than two days for any reason

Design outcomes

Primary

MeasureTime frameDescription
Measurements to Assess General Cognitive FunctionBaseline, 1 and 6 monthsChange in Mini Mental State Examination (minimum value 10 - maximum value 30, higher scores mean a better outcome)
Neuropsychological AssessmentBaseline, 1 and 6 monthsChange Test (higher scores mean a better outcome)
Changes in Functional Cognitive StateBaseline, 1 and 6 monthsGlobal Deterioration Scale (values 1-7, higher scores mean a worse outcome)

Secondary

MeasureTime frameDescription
NeuroImagingbaseline, 1 month, 6 monthsMagnetic Resonance Imaging (MRI) (white matter hyperintensities volume)
NeurophysiologyBaseline, 1 month, 12 monthsChanges in Event-Related Potential (ERP) (oddball paradigm, auditory ERPs)
Electroencephalography recordingBaseline, 1 month, 6 monthsChanges in Electroencephalography (EEG), resting state

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026